Clinical trial NCT05472519: Immunopathology of Loeys-Dietz Syndrome
Official title: Immunopathology of Loeys-Dietz Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Loeys-Dietz Syndrome
Keywords: Loeys-Dietz Syndrome
immunology
T-Lymphocytes
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2022-07-25
Enrollment: 60
Sex: ALL
Minimum age (years): 5
Maximum age (years): 86
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Loeys-Dietz syndrome (LDS) is a rare vascular genetic disorder (estimated prevalence 1/25,000-1/100,000) due primarily to mutations in the Transforming growth factor beta (TGF-β) cytokine receptor 1 and 2 genes. In addition to a common vascular phenotype with Marfan syndrome (dilatation of the ascending aorta, arachnodactyly, lens dislocation), patients present specific malformations (bifid uvula, hypertelorism, tortuous arteries) and immuno-allergic manifestations (asthma, eczema, food allergy, eosinophilic esophagitis, chronic inflammatory bowel disease).

Pathophysiologically, LDS appears to be associated with hyperactivation of the intracellular TGF-β signaling pathway in a manner similar to Marfan syndrome, as evidenced by increased intracellular phosphorylated Smad2/3 (pSmad2/3) in lymphocytes. The immuno-allergic complications appear paradoxical because of the major immunosuppressive role of this cytokine on lymphoid and myeloid immune lineages.

The biological description of immunological abnormalities associated with LDS is based on a single 2013 study that found increased regulatory T (Treg) and Th2 lymphocyte polarizations, as well as increased circulating eosinophil and total IgE levels.

In order to better understand the underlying mechanisms, the investigators propose to perform a descriptive clinical-biological study to identify and study the immune subpopulations most impacted by the causative mutations of LDS.


Eligibility criteria: Inclusion Criteria:

For patients with Loeys-Dietz syndrome:

* Patients aged ≥ 5 years with Loeys-Dietz syndrome with a diagnosis confirmed by the presence of a TGF-βR 1 or R2 mutation known to be pathogenic to patients.
* Free, informed and signed consent from the patient or both parents or legal guardians for minor patients.
* Patient affiliated to a social security system or similar.

For healthy volunteers:

* Subjects aged ≥ 5 years.
* Free, informed and signed consent of the witness, or if applicable of both parents or legal representatives for minors.
* Patient affiliated to a social security system or similar.

Exclusion Criteria:

For patients with Loeys-Dietz syndrome:

* Patient with an evolving or recently healed (\< 3 months) cancer that could alter the immunologic profile.
* Patient with an evolving or recently healed (\< 3 months) infection that could alter the immunologic profile.
* Patient with a weight of less than 20 kg.
* Pregnant woman.
* Patient participating in another research study with an exclusion period exclusion period still in progress.

For healthy volunteers:

* Subject with an active or recently cured (\< 3 months) cancer that could alter the immunologic profile.
* Subject with an active or recently healed (\< 3 months) infection that could alter the immunological profile.
* Patient with a weight of less than 20 kg.
* Pregnant woman.
* Subject participating in another research study with an exclusion period exclusion period still in progress.
* Persons under court protection.

Primary outcomes:
measure: Percentage of circulating TFH lymphocyte subpopulation.
timeFrame: Day 1
Secondary outcomes:
measure: Intracellular pSmad2/3 labeling level of circulating TFH lymphocytes.
timeFrame: Day 1
measure: Identification of Immuno-allergic pathologies
timeFrame: Day 1
measure: Identification of serious infectious pathologies
timeFrame: Day 1
measure: Identification of Vascular complications
timeFrame: Day 1
measure: Identification morpho-skeletal complications
timeFrame: Day 1
Other outcomes:
Locations:
city: Bron
country: France
facility: Hôpital Femme-Mère-Enfant / Centre de Compétences pour le syndrome de Marfan et apparentés
Study officials:
References: